{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:20:50Z","timestamp":1791840050519,"version":"4.3.4"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["JUSRP123080"],"award-info":[{"award-number":["JUSRP123080"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073551"],"award-info":[{"award-number":["82073551"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clnu.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T01:56:43Z","timestamp":1712973403000},"page":"1224-1239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Yafang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindi","family":"Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8430-9467","authenticated-orcid":false,"given":"Da","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiju","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-5497","authenticated-orcid":false,"given":"Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2024.04.004_bib1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2024.04.004_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0035-1562942","article-title":"Diagnosis and assessment of NAFLD: definitions and histopathological classification","volume":"35","author":"Burt","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clnu.2024.04.004_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s10620-013-2998-x","article-title":"From nonalcoholic Fatty liver disease to hepatocellular carcinoma: a systems understanding","volume":"59","author":"Rozman","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ajg.2010.310","article-title":"Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?","volume":"106","author":"Arendt","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clnu.2024.04.004_bib7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hep.25805","article-title":"Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study","volume":"56","author":"Bell","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2024.04.004_bib8","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.3748\/wjg.v20.i36.12956","article-title":"Non-alcoholic fatty liver disease: what the clinician needs to know","volume":"20","author":"Machado","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clnu.2024.04.004_bib9","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jhep.2010.08.030","article-title":"A\u00a0randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis","volume":"54","author":"Ratziu","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1475-2840-11-61","article-title":"Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?","volume":"11","author":"Shargorodsky","year":"2012","journal-title":"Cardiovascular Diabetol"},{"key":"10.1016\/j.clnu.2024.04.004_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1089\/ars.2017.7330","article-title":"Questionnaire-based anti-inflammatory diet index as a predictor of low-grade systemic inflammation","volume":"28","author":"Kaluza","year":"2018","journal-title":"Antioxidants Redox Signaling"},{"key":"10.1016\/j.clnu.2024.04.004_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/JIR.S155903","article-title":"Systemic low-grade inflammation in post-traumatic stress disorder: a systematic review","volume":"11","author":"Speer","year":"2018","journal-title":"J\u00a0Inflammation Res"},{"key":"10.1016\/j.clnu.2024.04.004_bib13","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1080\/10408398.2018.1458021","article-title":"Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of clinical trials: synbiotic supplementation and NAFLD","volume":"59","author":"Hadi","year":"2019","journal-title":"Critical RevFood Sci Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3390\/nu9101124","article-title":"Gut microbiota and nonalcoholic fatty liver disease: insights on mechanisms and therapy","volume":"9","author":"Ma","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.04.004_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/jhep.2003.50048","article-title":"Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease","volume":"37","author":"Li","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2024.04.004_bib16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jhep.2008.05.025","article-title":"Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells","volume":"49","author":"Ma","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/hep.22711","article-title":"VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice","volume":"49","author":"Velayudham","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2024.04.004_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clnesp.2020.06.020","article-title":"The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial","volume":"39","author":"Khadijeh","year":"2020","journal-title":"Clinical Nutr ESPEN"},{"key":"10.1016\/j.clnu.2024.04.004_bib19","first-page":"531","article-title":"Effect of a probiotic and metformin on liver aminotransferases in non-alcoholic steatohepatitis: a double blind randomized clinical trial","volume":"4","author":"Shavakhi","year":"2013","journal-title":"International J Prevent Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib20","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Vahideh","year":"2020","journal-title":"J\u00a0Food Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib21","doi-asserted-by":"crossref","first-page":"100769","DOI":"10.1016\/j.aohep.2022.100769","article-title":"Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study","volume":"28","author":"Alrutz Barcelos","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib22","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP BCMC strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.04.004_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.880014","article-title":"Effects of synbiotics, probiotics, and prebiotics on liver enzymes of patients with non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"9","author":"Kanchanasurakit","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib24","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3920\/BM2020.0183","article-title":"Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis","volume":"12","author":"Jin","year":"2021","journal-title":"Beneficial Microb"},{"key":"10.1016\/j.clnu.2024.04.004_bib25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"10.1016\/j.clnu.2024.04.004_bib26","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.clnu.2024.04.004_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS one"},{"key":"10.1016\/j.clnu.2024.04.004_bib28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/(SICI)1097-0258(19960630)15:12<1237::AID-SIM301>3.0.CO;2-N","article-title":"Meta-analysis in the design and monitoring of clinical trials","volume":"15","author":"DerSimonian","year":"1996","journal-title":"Statistics Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clnu.2024.04.004_bib30","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1002\/sim.9428","article-title":"Accounting for publication bias using a bivariate trim and fill meta-analysis procedure","volume":"41","author":"Luo","year":"2022","journal-title":"Statistics Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clnesp.2020.06.020","article-title":"The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: a randomized, placebo-controlled, clinical trial","volume":"39","author":"Abhari","year":"2020","journal-title":"Clinical Nutr ESPEN"},{"key":"10.1016\/j.clnu.2024.04.004_bib32","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"Int J Prevent Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib34","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.42902","article-title":"The effect of synbiotic supplementation on body composition and lipid profile in patients with NAFLD: a randomized, double blind, placebo-controlled clinical trial study","volume":"19","author":"Asgharian","year":"2017","journal-title":"Iran Red Crescent Med J"},{"key":"10.1016\/j.clnu.2024.04.004_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/biomedicines11020640","article-title":"The effects of probiotics on small intestinal microbiota composition, inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease","volume":"11","author":"Ayob","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.clnu.2024.04.004_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2022.100769","article-title":"Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study","volume":"28","author":"Barcelos","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib37","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J\u00a0Food Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.15171\/mejdd.2017.66","article-title":"Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: a randomized clinical trial","volume":"9","author":"Behrouz","year":"2017","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.clnu.2024.04.004_bib39","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021464","article-title":"Protective effect of probiotics in patients with non-alcoholic fatty liver disease","volume":"99","author":"Cai","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.clnu.2024.04.004_bib40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12876-021-01660-5","article-title":"A\u00a0randomised placebo controlled trial of VSL#3(\u00ae) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease","volume":"21","author":"Chong","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.clnu.2024.04.004_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.846873","article-title":"Probiotic therapy with VSL#3(\u00ae) in patients with NAFLD: a randomized clinical trial","volume":"9","author":"Derosa","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000315","article-title":"High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study","volume":"6","author":"Duseja","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.clnu.2024.04.004_bib43","first-page":"106","article-title":"Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial","volume":"21","author":"Ekhlasi","year":"2016","journal-title":"J\u00a0Res Med Sci: Off J Isfahan Univ Med Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib44","first-page":"278","article-title":"Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease","volume":"16","author":"Ekhlasi","year":"2017","journal-title":"Excli J"},{"key":"10.1016\/j.clnu.2024.04.004_bib45","first-page":"1984","article-title":"Probiotic supplementation, hepatic fibrosis, and the microbiota profile in patients with nonalcoholic steatohepatitis: a randomized controlled trial","volume":"153","author":"Escouto","year":"2023","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3945\/ajcn.113.068890","article-title":"Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study","volume":"99","author":"Eslamparast","year":"2014","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/nu8070397","article-title":"Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis","volume":"8","author":"Ferolla","year":"2016","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.04.004_bib48","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.46017","article-title":"The effect of probiotic and\/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: a double blind randomized clinical trial","volume":"19","author":"Javadi","year":"2017","journal-title":"Iran Red Crescent Med J"},{"key":"10.1016\/j.clnu.2024.04.004_bib49","first-page":"131","article-title":"The potential role of probiotics or\/and prebiotic on serum lipid profile and insulin resistance in alcoholic fatty liver disease: A double blind randomized clinical trial","volume":"4","author":"Javadi","year":"2017","journal-title":"J\u00a0Med Biol Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib50","first-page":"1031","article-title":"Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease","volume":"27","author":"Javadi","year":"2018","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib51","doi-asserted-by":"crossref","first-page":"418","DOI":"10.23736\/S0026-4806.18.05845-7","article-title":"Beneficial effects of probiotic combination with omega-3 fatty acids in NAFLD: a randomized clinical study","volume":"109","author":"Kobyliak","year":"2018","journal-title":"Minerva Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5603\/DK.2019.0016","article-title":"Probiotics and smectite absorbent gel formulation reduce liver stiffness, transaminase and cytokine levels in NAFLD associated with type 2 diabetes: a randomized clinical study","volume":"8","author":"Kobyliak","year":"2019","journal-title":"Clin Diabetol"},{"key":"10.1016\/j.clnu.2024.04.004_bib53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A\u00a0multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J\u00a0Gastrointest Liver Diseases: JGLD"},{"key":"10.1016\/j.clnu.2024.04.004_bib54","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.3390\/nu15133039","article-title":"Effect of a probiotic and a synbiotic on body fat mass, body weight and traits of metabolic syndrome in individuals with abdominal overweight: a human, double-blind, randomised, controlled clinical study","volume":"15","author":"Laue","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.04.004_bib55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10620-011-1887-4","article-title":"Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis","volume":"57","author":"Malaguarnera","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib56","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J\u00a0Digestive Diseases"},{"key":"10.1016\/j.clnu.2024.04.004_bib57","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1017\/S0007114517000204","article-title":"Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial","volume":"117","author":"Mofidi","year":"2017","journal-title":"Br J Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib58","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP(\u00ae) BCMC(\u00ae) strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.clnu.2024.04.004_bib59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7762\/cnr.2021.10.1.36","article-title":"Probiotic yogurt fortified with vitamin D can improve glycemic status in non-alcoholic fatty liver disease patients: a randomized clinical trial","volume":"10","author":"Morvaridzadeh","year":"2021","journal-title":"Clin Nutr Res"},{"key":"10.1016\/j.clnu.2024.04.004_bib60","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"J\u00a0Dairy Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib61","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jff.2015.08.031","article-title":"Probiotic yogurt improves body mass index and fasting insulin levels without affecting serum leptin and adiponectin levels in non-alcoholic fatty liver disease (NAFLD)","volume":"18","author":"Nabavi","year":"2015","journal-title":"J\u00a0Funct Foods"},{"key":"10.1016\/j.clnu.2024.04.004_bib62","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3350\/cmh.2018.0006","article-title":"Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease","volume":"24","author":"Sayari","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib63","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clnu.2024.04.004_bib64","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J\u00a0Am Coll Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib65","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib66","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.clnu.2024.04.004_bib67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.47203\/IJCH.2019.v31i01.009","article-title":"Probiotic and lifestyle modification in obese pediatrics with non-alcoholic fatty liver disease","volume":"31","author":"Goyal","year":"2019","journal-title":"Indian J Community Health"},{"key":"10.1016\/j.clnu.2024.04.004_bib68","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ijo.2015.40","article-title":"Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment","volume":"39","author":"Miccheli","year":"2005","journal-title":"Int J Obes"},{"key":"10.1016\/j.clnu.2024.04.004_bib69","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3345\/cep.2021.00787","article-title":"Effects of probiotics combined with dietary and lifestyle modification on clinical, biochemical, and radiological parameters in obese children with nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis: a randomized clinical trial","volume":"65","author":"Rodrigo","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"10.1016\/j.clnu.2024.04.004_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib71","article-title":"Effect of synbiotic supplementation in children with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"103","author":"Poparn","year":"2020","journal-title":"J\u00a0Med Assoc Thailand"},{"key":"10.1016\/j.clnu.2024.04.004_bib72","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/MPG.0b013e31821f9b85","article-title":"Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease","volume":"52","author":"Vajro","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib73","first-page":"418","article-title":"Probiotics and non-alcoholic fatty liver disease in children and adolescents: a systematic review. Rev Esp Enferm Dig: organo oficial de la Sociedad Espanola de Patologia","volume":"115","author":"Avelar-Rodriguez","year":"2022","journal-title":"Digestiva"},{"key":"10.1016\/j.clnu.2024.04.004_bib74","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr Rev"},{"key":"10.1016\/j.clnu.2024.04.004_bib75","article-title":"Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2024.04.004_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms7050121","article-title":"Role of gut microbiota in hepatocarcinogenesis","volume":"7","author":"Gupta","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.clnu.2024.04.004_bib77","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/19490976.2020.1712984","article-title":"Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome","volume":"11","author":"Lee","year":"2020","journal-title":"Gut Microb"},{"key":"10.1016\/j.clnu.2024.04.004_bib78","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/gutjnl-2019-320490","article-title":"Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis?","volume":"69","author":"Tilg","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.clnu.2024.04.004_bib79","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1002\/ctm2.634","article-title":"Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease","volume":"11","author":"Yu","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.773340","article-title":"Bifidobacterium adolescentis alleviates liver steatosis and steatohepatitis by increasing fibroblast growth factor 21 sensitivity","volume":"12","author":"Long","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clnu.2024.04.004_bib81","first-page":"2284","article-title":"Immunomodulatory and antioxidant potential of Lactobacillus exopolysaccharides","volume":"91","author":"Liu","year":"2011","journal-title":"J\u00a0Sci Food Agric"},{"key":"10.1016\/j.clnu.2024.04.004_bib82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.idairyj.2009.10.005","article-title":"Streptococcus thermophilus strains: multifunctional lactic acid bacteria","volume":"20","author":"Ramya","year":"2010","journal-title":"Int Dairy J"},{"key":"10.1016\/j.clnu.2024.04.004_bib83","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3389\/fmicb.2018.02214","article-title":"In\u00a0vitro probiotic potential and anti-cancer activity of newly isolated folate-producing Streptococcus thermophilus strains","volume":"9","author":"Tarrah","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.clnu.2024.04.004_bib84","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/hep4.1387","article-title":"Mortality risk detected by atherosclerotic cardiovascular disease score in patients with nonalcoholic fatty liver disease","volume":"3","author":"Golabi","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clnu.2024.04.004_bib85","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3748\/wjg.v27.i10.959","article-title":"Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"27","author":"Nadinskaia","year":"2021","journal-title":"World journal of gastroenterology"},{"key":"10.1016\/j.clnu.2024.04.004_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodres.2021.110490","article-title":"Protective and ameliorating effects of probiotics against diet-induced obesity: a review","volume":"147","author":"Tang","year":"2021","journal-title":"Food Res Int"},{"key":"10.1016\/j.clnu.2024.04.004_bib87","first-page":"106","article-title":"Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial","volume":"21","author":"Ekhlasi","year":"2016","journal-title":"J\u00a0Res Med Sci: Off J Isfahan Univ Med Sci"},{"key":"10.1016\/j.clnu.2024.04.004_bib88","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00394-019-01931-8","article-title":"The effect of probiotics on inflammatory biomarkers: a meta-analysis of randomized clinical trials","volume":"59","author":"Milajerdi","year":"2020","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib89","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2024.04.004_bib90","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.clnu.2024.04.004_bib91","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/10408398.2018.1547268","article-title":"Using probiotics for type 2 diabetes mellitus intervention: advances, questions, and potential","volume":"60","author":"Sun","year":"2020","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.clnu.2024.04.004_bib92","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.cimid.2009.11.002","article-title":"Suppression of proinflammatory cytokine production by specific metabolites of Lactobacillus plantarum 10hk2 via inhibiting NF-\u03baB and p38 MAPK expressions","volume":"33","author":"Chon","year":"2010","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.clnu.2024.04.004_bib93","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/biom12010056","article-title":"Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives","volume":"12","author":"Vallianou","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.clnu.2024.04.004_bib94","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13568-020-01038-y","article-title":"Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Amb Express"},{"key":"10.1016\/j.clnu.2024.04.004_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.609722","article-title":"Probiotic gastrointestinal transit and colonization after oral administration: a long journey","volume":"11","author":"Han","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.clnu.2024.04.004_bib96","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2018.08.041","article-title":"Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features","volume":"174","author":"Zmora","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.clnu.2024.04.004_bib97","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics Med"},{"key":"10.1016\/j.clnu.2024.04.004_bib98","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"Int J Epidemiol"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561424001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T01:43:26Z","timestamp":1716860606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561424001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0261561424001109"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2024.04.004","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.","name":"copyright","label":"Copyright"}]}}